Skip to content
Tenfell
Closed tender
Published 21 Jun 2021

NHS National Generic Pharmaceuticals Wave 13

NHS England · London

Key facts

Estimated value
£710,767,138
Closing date
26 Jul 2021
Contract starts
01 Feb 2022
Contract ends
31 May 2024
Procedure
Open procedure (below threshold)
Buyer type
Central government

Description

Tender Close: 26th July 2021, 13:00. Invitation to offer for NHS National Generic Pharmaceuticals Wave 13 Offer reference number: CM/PHG/17/5532 Period of framework agreement: The total maximum duration of the framework agreement to be no more than 28 months, with an option or options to extend (at the Authority's sole discretion) for a period or periods up to a total of 48 months.

Potential periods of call-offs under the framework agreement:

Transition (Everolimus) CESW: 1 March 2022 - 30 September 2023 (19 months) LSNE: 1 March 2022 - 31 January 2023 (11 months) NWLN: 1 March 2022 - 31 January 2023 (11 months)

Oral Products plus non-parenterals All Regions: 1 March 2022 - 31 May 2024 (27 months)

Hospital Only Products CESW: 1 February 2022 - 30 September 2023 (20 months) LSNE: 1 February 2022 - 31 May 2024 (28 months) NWLN: 1 February 2022 - 31 January 2023 (12 months)

Categories (CPV)

Similar open tenders

About NHS England

Their tenders, awards, contracts coming up for renewal, decision makers and committee papers.

View buyer profile

Their other open tenders

Published by the buyer on Contracts Finder archive (Open Contracting) (Open Government Licence v3.0). Always read the original notice before responding.